Pfizer: Breast Neoplasms trials

The registry lists 182 Breast Neoplasms studies with Pfizer as lead sponsor. 6 are open to participants now and 101 have results posted.

Phase 1 50Phase 2 56Phase 3 25Phase 4 3No phase 61(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruitingNCT07897721Phase 1
• A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerNot yet recruitingNCT07890597Phase 3
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsRecruitingNCT07318805Phase 1
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingNCT07062965Phase 3
• A Study to Learn More About Tukysa Once it is Out in the Korean MarketNot yet recruitingNCT06873191
• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingNCT04557449Phase 2
• A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopauseCompletedNCT06465368Phase 2Results posted
• A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.CompletedNCT06307457Results posted
• A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruitingNCT06206837Phase 1/2Results posted
• Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.CompletedNCT06086340Results posted
• A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.CompletedNCT05770713Results posted
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingNCT05654623Phase 3Results posted
• A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast CancerCompletedNCT05584644Results posted
• A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)Active, not recruitingNCT05463952Phase 1Results posted
• A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in DenmarkCompletedNCT05452798Results posted
• Real-World Effectiveness of Palbociclib in Combination With an Aromatase InhibitorCompletedNCT05361655Results posted
• Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.CompletedNCT05155566Results posted
• Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in JapanCompletedNCT05153187Results posted
• Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2mCompletedNCT05141708Results posted
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Phase 3Results posted
• A Study of PF-07260437 in Advanced or Metastatic Solid TumorsTerminatedNCT05067972Phase 1Results posted
• Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor AloneCompletedNCT05012644Results posted
• Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT04987931Results posted
• Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBCCompletedNCT04937660Results posted
• Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaCompletedNCT04803305Phase 1Results posted
• Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine MonotherapyCompletedNCT04736576Not applicableResults posted
• Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus LetrozoleCompletedNCT04735367Results posted
• A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingNCT04721977Phase 2Results posted
• A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsCompletedNCT04672460Phase 1Results posted
• A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.CompletedNCT04671615Results posted
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedNCT04539938Phase 2Results posted
• Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.CompletedNCT04460911Results posted
• RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.CompletedNCT04460898Results posted
• HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and OutcomesTerminatedNCT04396626Results posted
• Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination TherapyCompletedNCT04394247Results posted
• Real-world Treatment Patterns and Effectiveness of Palbociclib and AI TherapyCompletedNCT04176354Results posted
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerActive, not recruitingNCT03975647Phase 3Results posted
• UK Ibrance Patient Program (IPP) StudyCompletedNCT03921866Results posted
• PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsTerminatedNCT03685591Phase 1Results posted
• A Study of PF-06873600 in People With CancerTerminatedNCT03519178Phase 1/2Results posted
• Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast CancerTerminatedNCT03499353Phase 2Results posted
• A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid TumorsCompletedNCT03343054Phase 1Results posted
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsTerminatedNCT03330405Phase 1/2Results posted
• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT03310957Phase 1/2Results posted
• PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid TumorsTerminatedNCT03284723Phase 1Results posted
• Palbociclib in Real World PracticeCompletedNCT03280303Results posted
• Ibrance Real World InsightsCompletedNCT03159195Results posted
• Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast CancerCompletedNCT02679755Phase 4Results posted
• PF-06671008 Dose Escalation Study in Advanced Solid TumorsTerminatedNCT02659631Phase 1Results posted
• A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.CompletedNCT02650193Phase 2Results posted
• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerCompletedNCT02614794Phase 2Results posted
• Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed AppropriateCompletedNCT02600923Phase 3Results posted
• Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerCompletedNCT02499146Phase 1Results posted
• A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]CompletedNCT02297438Phase 3Results posted
• A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)CompletedNCT02187744Phase 3Results posted
• A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid TumorsTerminatedNCT02129205Phase 1Results posted
• A Study Of PF-06664178 In Patients With Advanced Solid TumorsTerminatedNCT02122146Phase 1Results posted
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)TerminatedNCT02034916Phase 2Results posted
• Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedNCT02007512Phase 2Results posted
• A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)CompletedNCT01989676Phase 3Results posted
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)CompletedNCT01945775Phase 3Results posted
• Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)CompletedNCT01942135Phase 3Results posted
• A Study Of PF-06263507 In Patients With Advanced Solid TumorsTerminatedNCT01891669Phase 1Results posted
• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerCompletedNCT01889238Phase 2Results posted
• A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast CancerTerminatedNCT01876251Phase 1Results posted
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)CompletedNCT01740427Phase 3Results posted
• A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast CancerCompletedNCT01684215Phase 2Results posted
• Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerCompletedNCT01597193Phase 1Results posted
• Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast CancerTerminatedNCT01430585Phase 2Results posted
• A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ PatientsTerminatedNCT01305239Results posted
• Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsCompletedNCT01286987Phase 1Results posted
• Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast CancerTerminatedNCT01239745Results posted
• Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast CancerCompletedNCT01237327Phase 3Results posted
• Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In ChinaCompletedNCT01176916Phase 4Results posted
• Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer PatientsTerminatedNCT01155063Results posted
• A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast CancerTerminatedNCT01121549Results posted
• Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast CancerCompletedNCT01061359Results posted
• Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)CompletedNCT01050634Results posted
• Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast CancerCompletedNCT01047358Results posted
• Figitumumab Combined With Pegvisomant For Advanced Solid TumorsTerminatedNCT00976508Phase 1Results posted
• Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast CancerTerminatedNCT00959946Phase 1/2Results posted
• Special Investigation For Patients With Renal And/Or Hepatic Disorders On AromasinCompletedNCT00932165Results posted
• Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast CancerTerminatedNCT00880009Phase 2Results posted
• Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast CancerTerminatedNCT00793546Phase 2Results posted
• An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With AromasinTerminatedNCT00776659Results posted
• Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast CancerCompletedNCT00721409Phase 2Results posted
• Study Of Sunitinib With Capecitabine In Breast CancerCompletedNCT00662025Phase 2Results posted
• Efficacy And Safety Of Sunitinib In Women With Advanced Breast CancerCompletedNCT00471276Phase 2Results posted
• A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast CancerCompletedNCT00435409Phase 3Results posted
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
• A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast CancerTerminatedNCT00417885Phase 1/2Results posted
• Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast CancerCompletedNCT00393939Phase 3Results posted
• A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast CancerCompletedNCT00373256Phase 3Results posted
• A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And CapecitabineTerminatedNCT00373113Phase 3Results posted
• Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerTerminatedNCT00372996Phase 2Results posted
• Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 PositiveCompletedNCT00372424Phase 1Results posted
• Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast CancerCompletedNCT00319254Phase 2Results posted
• Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast CancerCompletedNCT00291577Phase 1Results posted
• Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast CancerCompletedNCT00246571Phase 2Results posted